Capital Group funds disclose significant stake in Nykode Therapeutics

SMALLCAP World Fund, Inc. (SCWF) has announced the acquisition of additional shares in Nykode Therapeutics ASA, bringing its total ownership to 5.018% of the company's total voting rights and share capital as of October 10, 2025. This disclosure, made in accordance with the Norwegian Securities Trading Act, follows SCWF's purchase of 75,057 shares at a price of 2.1102 NOK per share on the same date. The transaction was facilitated through the Oslo Børs AS.

SCWF, a U.S.-registered mutual fund, now legally owns 16,387,015 shares of Nykode Therapeutics. Capital Research and Management Company (CRMC), SCWF's investment adviser, holds proxy voting authority for these shares. The Capital Group Companies, Inc. (CGC), the parent company of CRMC, also filed a corresponding notification that encompasses SCWF’s holdings. Neither CGC nor its affiliates hold shares for their own account, with all reported shares being managed under discretionary investment mandates.

The total voting rights and share capital figures of 326,546,444 were used for percentage calculations in the disclosure.